H2 Equity Partners acquires UK medical consumables provider, GBUK Group
H2 Equity Partners (“H2”) has announced that it agreed to acquire GBUK Group Limited (“GBUK”), a leading UK provider of medical consumables for the enteral & critical care market.
GBUK, based in Selby – Yorkshire, employs 70 FTE’s and has seen significant turnover growth in recent years. GBUK supplies a wide range of Enteral and Critical Care medical consumable products to the NHS, with sales to all 657 Acute Care Trusts in the UK. GBUK has a unique approach to the market with a wide product range which has enabled the business to grow at an impressive pace. H2 believe that these attributes will allow the business to continue to grow strongly and gain further market share in the coming years.
H2 Equity Partners plans to build on GBUK’s strong position in the medical consumables market to take the company forward. H2 and management will work together to expand the product range, increase penetration of existing and new customers. H2’s investment will support GBUK on its current organic growth trajectory whilst also allowing the business to target new opportunities both in the UK and abroad via both organic expansion and further complimentary acquisitions to strengthen the business.
H2 were supported in the transaction by Squire Patton Boggs providing legal advice with PwC and CIL performing financial and commercial due diligence respectively. Eversheds in Leeds and BCMS Corporate Finance represented the vendor. Yorkshire Bank provided acquisition financing as well as further working capital facilities.
About H2 Equity Partners
H2 Equity Partners is an independent private equity firm founded in 1991, active in the Benelux, the United Kingdom, Ireland and Germany. H2 has built an exceptional record of acquiring and growing fundamentally attractive businesses that have a combination of growth, operational or strategic improvement opportunities at the time of investment. H2 currently manages a portfolio of 14 companies generating over € 1.5 billion in sales.
Source: H2 Equity Partners